1 / 9

Ac225 Therapy for Prostate Cancer

Alpha PSMA Therapy has been proven effective for patients with advanced prostate cancer for whom surgical and other medical options have already exhausted themselves.

Abhishek15
Download Presentation

Ac225 Therapy for Prostate Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AC225 THERAPY FOR PROSTATE CANCER

  2. Alpha PSMA Therapy has been proven effective for patients with advanced prostate cancer for whom surgical and other medical options have already exhausted themselves. They offer a new ray of hope. The Department of Nuclear Medicine at Fortis Memorial Research Institute (FMRI), Gurugram, India, has treated more than 30 new patients of Castration Resistance Prostate Cancer (CRPC) with Ac225 PSMA Therapy. The results are extremely promising with 75-80% of patients showing evidence of significant radiological and biochemical response with prolonged duration of response.

  3. Alpha (Ac225) PSMA Therapy is an effective treatment modality for men with metastatic castration-resistant prostate cancer (mCRPC). It helps improve the quality of life by decreasing tumor growth rate and reducing pain.

  4. Ac-225-PSMA Therapy is a safe and tolerable treatment option for metastatic castration- resistant prostate cancer (mCRPC) patients who have been previously treated with chemotherapy. Trials and research have shown that significant improvement in survival and quality of life can be achieved even in patients with residual disease which otherwise have very limited options.

  5. At the 2018 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), research was presented that demonstrated the benefit of providing earlier Lu-177 PSMA Radioligand Therapy to patients with metastatic prostate cancer, which until now was only used on patients with an advanced stage of the disease. The research demonstrated a potential survival benefit and a superior response after early initiation of the therapy - patients who demonstrated a PSA decline of more than 50% after at least two PRLT cycles lived significantly longer.

  6. PSMA-based therapies have been proven effective for patients with advanced prostate cancer for whom surgical and other medical options have already exhausted themselves. They offer a new ray of hope.

  7. The Department of Nuclear Medicine at Fortis Memorial Research Institute (FMRI), Gurugram, India, has treated more than 30 new patients of Castration Resistance Prostate Cancer (CRPC) with Ac225 PSMA Therapy. The results are extremely promising with 75-80% of patients showing evidence of significant radiological and biochemical response with prolonged duration of response.

  8. VIDEO ON PSMA THERAPY Do check the Video on PSMA Therapy (Actinium vs Lutetium) by Doctor Ishita B Sen at Nuclear Medicine Therapy

  9. FOR MORE INFORMATION OR A FREE SECOND OPINION ABOUT YOUR CASE. Visit: https://nuclearmedicinetherapy.in/ Email Dr Ishita Sen at info@nuclearmedicinetherapy.in Call or WhatsApp Dr.Ishita Sen @ + 91 98111 27080 Address: Nuclear Oncology Department, Fortis Memorial Research Institute (FMRI), Sector 44, Gurgaon, Haryana INDIA

More Related